Drug development is an arduous and expensive exercise. We seek to produce innovative compounds efficiently and effectively.

Analyst Coverage

Analyst	Firm
Rachel McMinn, Ph.D.	Banc of America Securities Merrill Lynch
Ying Huang, Ph.D.	Barclays Capital
Brian Skorney	Brean Murrary Carret & Co.
George Farmer, Ph.D.	Canaccord Genuity, Inc.
Yaron Werber, M.D.	Citigroup
Phil Nadeau	Cowen & Co.
Adam Cutler	Credit Suisse
Terence Flynn	Goldman Sachs
Mark Schoenebaum	ISI Group
Liisa Bayko	JMP Securities
Geoffrey Meacham, Ph.D.	J.P. Morgan Securities
Howard Liang, Ph.D.	Leerink Swann and Company
David Friedman, M.D.	Morgan Stanley
Alan Carr, Ph.D.	Needham & Company
Edward Tenthoff	Piper Jaffray
Jason Kantor, Ph.D.	RBC Capital
Thomas Russo	Robert W. Baird
Geoffrey Porges	Sanford Bernstein LLC
Carol Werther	Summer Street Research
Marko Kozul	ThinkEquity
Matthew Roden, PhD	UBS Securities LLC
Brian Abrahams, M.D.	Wells Fargo
Katherine Xu	William Blair

Vertex Pharmaceuticals Incorporated is followed by the analyst(s) listed above. Please note that any opinions, estimates or forecasts regarding Vertex Pharmaceuticals Incorporated's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Vertex Pharmaceuticals Incorporated or its management. Vertex Pharmaceuticals Incorporated does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.